Want to see TCRT full AI Analyst Report?
TCRT Stock Chart & Stats
$2.92
-$0.04(-2.13%)
At close: 4:00 PM EST
$2.92
-$0.04(-2.13%)
Day’s Range― - ―
52-Week Range$1.67 - $6.20
Previous CloseN/A
Volume6.23K
Average Volume (3M)860.99K
Market Cap
$5.08M
Enterprise Value$5.07M
Total Cash (Recent Filing)$354.00K
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta-1.48
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding2,442,146
10 Day Avg. Volume2,529,145
30 Day Avg. Volume860,987
Financial Highlights & Ratios
PEG Ratio0.06
Price to Book (P/B)2.92
Price to Sales (P/S)1258.64
P/FCF Ratio-2.12
Enterprise Value/Market Cap1.00
Enterprise Value/Revenue1.69K
Enterprise Value/Gross Profit-26.67
Enterprise Value/Ebitda-1.24
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Innovative Therapy PlatformAlaunos' proprietary TCR therapy platform harnesses the immune system to target cancer cells, offering a durable competitive advantage in oncology.
No DebtAlaunos' lack of debt reduces financial risk, providing flexibility to pursue strategic initiatives without the burden of interest obligations.
Board Alignment With EquityBoard's decision to receive equity compensation aligns their interests with shareholders, potentially driving long-term strategic focus and performance.
Bears Say
Negative Cash FlowOngoing negative cash flow indicates operational cash outflows exceed inflows, necessitating external funding and impacting financial sustainability.
Lack Of ProfitabilityPersistent unprofitability and widening losses challenge Alaunos' ability to sustain operations and invest in growth without external capital.
Declining Equity BaseA declining equity base signals potential financial instability, limiting Alaunos' capacity to absorb losses and invest in future growth.
Alaunos Therapeutics News
TCRT FAQ
What was Alaunos Therapeutics’s price range in the past 12 months?
Alaunos Therapeutics lowest stock price was $1.67 and its highest was $6.20 in the past 12 months.
What is Alaunos Therapeutics’s market cap?
Alaunos Therapeutics’s market cap is $5.08M.
When is Alaunos Therapeutics’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Alaunos Therapeutics’s earnings last quarter?
Currently, no data Available
Is Alaunos Therapeutics overvalued?
According to Wall Street analysts Alaunos Therapeutics’s price is currently Overvalued.
Does Alaunos Therapeutics pay dividends?
Alaunos Therapeutics does not currently pay dividends.
What is Alaunos Therapeutics’s EPS estimate?
Alaunos Therapeutics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Alaunos Therapeutics have?
Alaunos Therapeutics has 2,442,146 shares outstanding.
What happened to Alaunos Therapeutics’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Alaunos Therapeutics?
Currently, no hedge funds are holding shares in TCRT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Alaunos Therapeutics
Alaunos Therapeutics, Inc. is an oncology company in the clinical trial phase, specializing in the creation of adoptive T-cell receptor (TCR) engineered therapies. Their pipeline includes a TCR Library, currently undergoing Phase I/II clinical trials, which comprises ten T-cell receptors designed to target mutated KRAS, TP53, and EGFR in various cancers such as non-small cell lung, colorectal, endometrial, pancreatic, ovarian, and bile duct cancers. Additionally, they are advancing hunTR, a platform focused on human neoantigen T-cell receptors, and mbIL-15, intended for solid tumor treatment. The company maintains strategic collaborations, including a licensing agreement with PGEN Therapeutics, Inc., a research and development partnership with The University of Texas MD Anderson Cancer Center, and both a patent licensing and R&D agreement with the National Cancer Institute. Previously known as ZIOPHARM Oncology, Inc., the company adopted its current name, Alaunos Therapeutics, Inc., in January 2022. Its headquarters are located in Houston, Texas.
Technical Analysis
Ownership Overview
8.60% Insiders
2.32% Mutual Funds
<0.01% Other Institutional Investors
88.51% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---